Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas
Last week’s US House and Senate hearings on drug pricing underscore how quickly the negative attention has turned to industry. With more public discussions planned – including potential testimony from pharma execs – here’s what can be expected in the months ahead.
You may also be interested in...
Calls to exercise “march in” rights on federal patents licensed to pharmaceutical companies are a recurring theme in the US drug pricing debate. Now the Department of Commerce is proposing to make those threats even emptier than they already are.
Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.
Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.